Twenty years of MOPP therapy for Hodgkin's disease.

Abstract

The results of treatment of 198 patients with MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) for Hodgkin's disease were analyzed after a median of 14 years of follow-up. Throughout the period of follow-up, 103 patients have remained continuously free of disease. Review of biopsy specimens of 43 patients originally classified as Hodgkin's disease, lymphocyte-depleted type, revealed that ten of these patients actually had diffuse immunoblastic or large cell non-Hodgkin's lymphomas. Of the 188 patients with Hodgkin's disease, 157 achieved a complete response (CR) (84%), and 66% of them (101 patients) have remained disease-free more than 10 years from the end of treatment. Absence of B symptoms and receiving higher doses of vincristine were factors associated with a higher CR rate and longer survival. Patients entering complete remission in five cycles or less had significantly longer remissions than those requiring six or more cycles. Forty-eight percent of the Hodgkin's disease patients have survived between 9 and 21 years (median, 14 years) from the end of treatment. Nineteen percent of the CRs have died of intercurrent illnesses, free of Hodgkin's disease.

ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial

“…Long-term survival was observed in approximately half of the patients treated with these regimens (Longo et al, 1986;Linch and Vaughan Hudson, 1988).…”

Hodgkin lymphoma: MOPP chemotherapy to PD‐1 blockade and beyond

“…The long-term outcomes of the MOPP regimen showed this to be an effective combination resulting in a progression free survival of 54% and an overall survival of 48% with 20 years of follow-up [4]. Although the MOPP chemotherapy regimen significantly changed the outcome of patients who previously had evidence of disease progression and subsequently died of disease, approximately one-third of patients treated with MOPP chemotherapy still had evidence of disease progression.…”

Prognostic factors for survival in stage IIIB and IV Hodgkin's disease: a multivariate analysis comparing two specialist treatment centres

“…Neither performance status (Bakemeier et a., 1984;Jones et al, 1982) nor stage (DeVita et al, 1980;Bakemeier et al, 1984) have been of consistent significance in univariate analysis. In most reports sex has not been an independent prognostic factor, although Longo et al (1986) found that it contributed to the prediction of tumour related mortality when considered in combination with clinical liver involvement and pleural involvement. This factor was however significant previously (Wagstaff et al, 1986) This agreement in results reported in this analysis was not reached immediately.…”

“…Only DeVita et al (1980) found histological subtype to be important, patients E. = 47 with nodular sclerosing pathology having a significantly shorter survival than the rest. However, a recent review of these data (Kant et al, 1986;Longo et al, 1986) showed histology to no longer be of independent prognostic significance. Schilling et al (1982) found serum LDH to be (Wagstaff et al, 1986).…”